Global Biosimilar Monoclonal Antibodies Market Latest Trends and Future Opportunities Analysis to 2030

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Biosimilar Monoclonal Antibodies Market Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Request for Sample Pages:
According to the latest research by InsightAce Analytic, the global biosimilar monoclonal antibodies market is valued at US$ XX million, and it is expected to reach US$ XX million by 2030, with a CAGR of XX% during the forecast period (2020-2030). By region, North America dominated the market with a share of XX% in 2020.

Get Free Sample Copy of Report :
https://www.insightaceanalytic.com/request-sample/1218

Biosimilars are biotherapeutic products. They are equivalent in terms of quality, efficacy, and safety to an innovative reference medicinal product. The mAb biosimilars are complex biological macromolecules with various post-translation modifications. These biosimilars are extensively used in treating many chronic, inflammatory, and autoimmune diseases. Various governing bodies regulate biosimilars in different countries, such as the FDA in the US and the European Medicines Agency (EMEA) in Europe.

The growth of the global biosimilar monoclonal antibodies market can be attributed to several factors, such as the increasing demand for cost-effective biosimilars, rising production of advanced monoclonal antibodies, growing geriatric population, high prevalence of chronic diseases, like cancer, kidney failure, rheumatoid arthritis, psoriasis, diabetes, and others. Besides, increasing patent expiries of many mAbs are expected to boost the market growth opportunities over the forecast years. Increased patent expiries of top-selling antibodies have encouraged pharmaceutical companies to develop biosimilars for mAbs, likely to drive the market during the forecast period.

However, the market growth is expected to be hindered by the complexities in manufacturing biological drugs, the scarcity of clinical trial expertise, strict government policies for product approvals, and the lack of knowledge and understanding among manufacturers about biosimilars regulation and approval.

Geographically, the Asia Pacific region is expected to witness significant growth over the forecast period (2020-2030) due to the increasing prevalence of chronic diseases, the growing need for cost-effective treatments, and the rising government funding for improving healthcare facilities.

Request for ToC/Proposal:
Major market players operating in the biosimilar monoclonal antibodies market include Pfizer (US), Novartis (Switzerland), Allergan (Ireland), Coherus BioSciences (US), Biocon (Bengaluru), Amgen (US), Boehringer Ingelheim (Germany), Celltrion (South Korea), BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia) among others.

Key developments in the market:
In July 2021, Abzena (UK), and BioXpress Therapeutics (Switzerland) collaborated to support biosimilar development for third-party customers. This partnership created an integrated solution between two leading service providers in biosimilar development and GMP manufacture.
In February 2020, Mylan (US) launched its trastuzumab biosimilar, Ogivri. Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2)-receptor-positive breast cancer, previously marketed by Genentech as Herceptin.
In June 2019, Amgen (US) and Allergan (Ireland) announced the FDA approval for KANJINTI™ (trastuzumab-anns). It is approved for all indications of the reference product, Herceptin® (trastuzumab), providing an additional treatment option for patients across three types of cancer.

Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1218

Market Segments
Global Biosimilar Monoclonal Antibodies Market, by Product, 2020-2030 (Value US$ Mn)
Infliximab
Trastuzumab
Rituximab
Adalimumab
Bevacizumab
Cetuximab
Ranibizumab
Denosumab
Eculizumab
Other Pipeline Products

Global Biosimilar Monoclonal Antibodies Market, by Indication, 2020-2030 (Value US$ Mn)
Oncology
Inflammatory & Autoimmune Disorders
Chronic Diseases
Blood Disorders
Other Indication

Global Biosimilar Monoclonal Antibodies Market, by Region, 2020-2030 (Value US$ Mn)
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

North America Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
U.S.
Canada

Europe Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
Germany
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
India
China
Japan
South Korea
Australia & New Zealand

Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
Brazil
Mexico
Rest of Latin America

Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
GCC Countries
South Africa
Rest of Middle East & Africa

Why should buy this report:
To receive a comprehensive analysis of the prospects for the global biosimilar monoclonal antibodies market
To receive an industry overview and future trends in the biosimilar monoclonal antibodies market
To analyze the biosimilar monoclonal antibodies market drivers and challenges
To get information on the biosimilar monoclonal antibodies market size (Value US$ Mn) & forecast to 2030
Significant investments, mergers & acquisitions in the biosimilar monoclonal antibodies market industry

For More Information @
https://www.insightaceanalytic.com/report/global-biosimilar-monoclonal-antibodies-market/1218

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

Corporate Office :
Office No.3050, 3rd Floor Marvel Fuego, Magarpatta Rd, Hadapsar, Pune, Maharashtra 411028

Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
info@insightaceanalytic.com

info@insightaceanalytic.com
North America:
+1 551 226 6109
Asia:
+91 79 72967118

This release was published on openPR.